Pre- and post-operative CD26+/CD326− CTC-negative patients showed an increase in the three-year PFS rate of 42 and 86%, respectively, with a reduction of the relative risk of tumor relapse to >90% (Fig. 3). Here, DPP4 is linked to neoplasm.